Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ksq-001ex, interleukin-2, cyclophosphamide, fludarabine | POLA1 | Direct | 2 | ||||||||
| aldesleukin, biopsy, biospecimen collection, computed tomography, cyclophosphamide, excisional biopsy, fludarabine, magnetic resonance imaging, standard treatment, therapeutic tumor infiltrating lymphocytes | POLA1 | Direct | 1 | ||||||||
| autologous mesothelin-specific tcr-t cells, cyclophosphamide, fludarabine, bendamustine | POLA1 | Direct | 1 | ||||||||
| bendamustine, biopsy, biospecimen collection, computed tomography, cyclophosphamide, echocardiography, fludarabine, leukapheresis, magnetic resonance imaging, multigated acquisition scan, positron emission tomography, t-cell receptor-engineered t-cells | POLA1 | Direct | 1 | ||||||||
| busulfan, anti-thymocyte globulin, fludarabine, cyclosporine, mycophenolate mofetil | POLA1 | Direct | 1 | ||||||||
| chemotherapy, cladribine, radiation therapy | POLA1 | Direct | 1 | ||||||||
| cyclophosphamide, fludarabine, aldesleukin, anti-hcd70 car transduced pbl | POLA1 | Direct | 1 | ||||||||
| cyclophosphamide, fludarabine, mutant kras g12v-specific tcr transduced autologous t cells, anti-pd-1 monoclonal antibody | POLA1 | Direct | 1 | ||||||||
| e7 tcr cells, aldesleukin, fludarabine, cyclophosphamide | POLA1 | Direct | 1 | ||||||||
| epidermal growth factor receptor(egfrv)iii chimeric antigen receptor (car) transduced pbl, aldesleukin, fludarabine, cyclophosphamide | POLA1 | Direct | 1 | ||||||||
| fludarabine, cyclophosphamide, ima101 product, recombinant human interleukin-2, imadetect, atezolizumab | POLA1 | Direct | 1 | ||||||||
| ft500, nivolumab, pembrolizumab, atezolizumab, cyclophosphamide, fludarabine, il-2 | POLA1 | Direct | 1 | ||||||||
| ibrutinib, fludarabine | POLA1 | Direct | 1 | ||||||||
| kras tcr-transduced pbl, aldesleukin, fludarabine, cyclophosphamide | POLA1 | Direct | 1 | ||||||||
| mycophenolate mofetil, tacrolimus, post-transplant cyclophosphamide, total body irradiation, hematopoietic cell transplant, jsp191, cyclophosphamide, fludarabine | POLA1 | Direct | 1 | ||||||||
| tc-510, fludarabine, cyclophosphamide | POLA1 | Direct | 1 | ||||||||
| tc-n201 cells, il-2, fludarabine, cyclophosphamide, nab-paclitaxel | POLA1 | Direct | 1 | ||||||||
| tcr-t cells, fludarabine, cyclophosphamide capsules, albumin-bound paclitaxel, il-2 | POLA1 | Direct | 1 | ||||||||
| total body irradiation (tbi), thiotepa, cyclophosphamide, busulfan, melphalan, fludarabine | POLA1 | Direct | 1 | ||||||||
| trop2-car-nk, cyclophosphamide, fludarabine | POLA1 | Direct | 1 | ||||||||
| tumor infiltrating lymphocytes (til), cyclophosphamid, fludarabine, interleukin-2, pembrolizumab | POLA1 | Direct | 1 | ||||||||
| tumor infiltrating lymphocytes (til), cyclophosphamide, fludarabine, interleukin-2, pembrolizumab | POLA1 | Direct | 1 | ||||||||
| young til, aldesleukin, cyclophosphamide, fludarabine, pembrolizumab (keytruda) | POLA1 | Direct | 1 | ||||||||
| clofarabine | POLA1 | Direct | yes | 0 | |||||||
| cytarabine | POLA1 | Direct | yes | 0 | |||||||
| fludarabine phosphate | POLA1 | Direct | yes | 0 | |||||||
| gemcitabine | POLA1 | Direct | yes | 0 | |||||||
| gemcitabine hydrochloride | POLA1 | Direct | yes | 0 | |||||||
| nelarabine | POLA1 | Direct | yes | 0 | |||||||
| adagrasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| afatinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| dacomitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| erlotinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| gefitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| sotorasib | KRAS | SSL via KRAS | yes | 2 | |||||||
| lazertinib and amivantamab | EGFR | SSL via EGFR | 1 | ||||||||
| osimertinib | EGFR | SSL via EGFR | yes | 1 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | ABL1 | SSL via ABL1 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | ABL1 | SSL via ABL1 | 4 | ||||||||
| ab122, ab122, tas-116, ab122, tas-116, ab122, tas-116, ab122, tas-120, ab122, tas-115, ab122, tas-115, ab122, tas-102, ramucirumab, ab122, tas-102, bevacizumab, ab122, ab122, tas-120, fluorouracil, cisplatin, ab122, tas-120, ab154, ab122, tas-120, fluorouracil, carboplatin, cisplatin, ab122, tas-120, ab154, ab122, tas-120, carboplatin, nab-paclitaxel, ab122, tas-120, cisplatin, gemcitabine, ab122, tas-120, nab-paclitaxel, gemcitabine | TYMS | SSL via TYMS | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | ABL1 | SSL via ABL1 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | FYN | SSL via FYN | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | MAPK1 | SSL via MAPK1 | 3 | ||||||||
| capecitabine, cisplatin | TYMS | SSL via TYMS | 3 | ||||||||
| futibatinib, pembrolizumab, cisplatin, 5-fu, oxaliplatin, leucovorin, levoleucovorin, irinotecan | TOP1 | SSL via TOP1 | 3 | ||||||||
| gemcitabine | TYMS | SSL via TYMS | 3 | ||||||||
| lurbinectedin, irinotecan | TOP1 | SSL via TOP1 | 3 | ||||||||
| srf617, gemcitabine, albumin-bound paclitaxel, pembrolizumab | TYMS | SSL via TYMS | 3 | ||||||||
| 5-fu, atezolizumab, bevacizumab, gemcitabine, leucovorin, nab-paclitaxel, oxaliplatin, capecitabine, cisplatin | TYMS | SSL via TYMS | 2 | ||||||||
| ab598, zimberelimab, fluorouracil, leucovorin, oxaliplatin | TYMS | SSL via TYMS | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | ABL1 | SSL via ABL1 | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | TYMS | SSL via TYMS | 2 | ||||||||
| alendronate, etidronate, ibandronate, risedronate, raloxifene | ESR1 | SSL via ESR1 | 2 | ||||||||
| apatinib, irinotecan | TOP1 | SSL via TOP1 | 2 | ||||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | TOP1 | SSL via TOP1 | 2 | ||||||||
| asp2138, pembrolizumab, oxaliplatin, leucovorin, fluorouracil, ramucirumab, paclitaxel, irinotecan | TYMS | SSL via TYMS | 2 | ||||||||
| asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine | TOP1 | SSL via TOP1 | 2 | ||||||||
| asp3082, cetuximab, leucovorin, oxaplatin, fluorouracil, irinotecan, nanoparticle albumin-bound-paclitaxel, gemcitabine | TYMS | SSL via TYMS | 2 | ||||||||
| avelumab, lorlatanib, talazoparib, pemetrexed, axitinib, cmp 001, utomilumab, pf04518600 | TYMS | SSL via TYMS | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | ABL1 | SSL via ABL1 | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | FYN | SSL via FYN | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | TYMS | SSL via TYMS | 2 | ||||||||
| bevacizumab, oxaliplatin, leucovorin calcium, fluorouracil, therapeutic conventional surgery, laboratory biomarker analysis | TYMS | SSL via TYMS | 2 | ||||||||
| biospecimen collection, computed tomography, devimistat, fluorouracil, gemcitabine hydrochloride, hydroxychloroquine, magnetic resonance imaging | TYMS | SSL via TYMS | 2 | ||||||||
| biospecimen collection, computed tomography, pemetrexed | TYMS | SSL via TYMS | 2 | ||||||||
| bryostatin 1, paclitaxel | CASP8 | SSL via CASP8 | 2 | ||||||||
| capecitabine | TYMS | SSL via TYMS | yes | 2 | |||||||
| capecitabine, carboplatin, epirubicin hydrochloride | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, docetaxel | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, irinotecan hydrochloride | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, oxaliplatin | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, oxaliplatin, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, adjuvant therapy, biopsy, conventional surgery, neoadjuvant therapy, quality-of-life assessment, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| capecitabine, temozolomide | TYMS | SSL via TYMS | 2 | ||||||||
| carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cetuximab, cisplatin, fluorouracil, conventional surgery | TYMS | SSL via TYMS | 2 | ||||||||
| cetuximab, cisplatin, irinotecan, radiation therapy, surgery | TOP1 | SSL via TOP1 | 2 | ||||||||
| chemotherapy, cisplatin, fluorouracil, low-let electron therapy, low-let photon therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, fluorouracil, conventional surgery, neoadjuvant therapy, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, fluorouracil, iressa, conventional surgery, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, fluorouracil, paclitaxel, conventional surgery, neoadjuvant therapy, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, fluorouracil, paclitaxel, surgical procedure, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, fluorouracil, surgical procedure, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| cisplatin, pemetrexed, gemcitabine, carboplatin, certolizumab, nivolumab | TYMS | SSL via TYMS | 2 | ||||||||
| durvalumab, tremelimumab, oxaliplatin, capecitabine, radiotherapy, paclitaxel, carboplatin, 5-fluorouracil (5-fu), leucovorin, docetaxel | TYMS | SSL via TYMS | 2 | ||||||||
| eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab | ESR1 | SSL via ESR1 | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | JAK2 | SSL via JAK2 | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | TNK2 | SSL via TNK2 | 2 | ||||||||
| erlotinib hydrochloride, oxaliplatin, fluorouracil, radiation therapy, conventional surgery, immunohistochemistry staining method, positron emission tomography, computed tomography, laboratory biomarker analysis, gene expression analysis, fludeoxyglucose f 18 | TYMS | SSL via TYMS | 2 | ||||||||
| filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| filgrastim, pegfilgrastim, cisplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| fluorouracil, gemcitabine hydrochloride, leucovorin calcium | TYMS | SSL via TYMS | 2 | ||||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study | TYMS | SSL via TYMS | 2 | ||||||||
| fluorouracil, irinotecan hydrochloride, leucovorin calcium, vorinostat, pharmacological study | TYMS | SSL via TYMS | 2 | ||||||||
| fluorouracil, oxaliplatin, conventional surgery, radiation therapy | TYMS | SSL via TYMS | 2 | ||||||||
| gefitinib, fulvestrant, erlotinib | ESR1 | SSL via ESR1 | 2 | ||||||||
| inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide | TOP1 | SSL via TOP1 | 2 | ||||||||
| inbrx-109, carboplatin, cisplatin, pemetrexed, 5-fluorouracil, irinotecan, temozolomide | TYMS | SSL via TYMS | 2 | ||||||||
| ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib | JAK2 | SSL via JAK2 | 2 | ||||||||
| ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib | TYMS | SSL via TYMS | 2 | ||||||||
| irinotecan, capecitabine | TOP1 | SSL via TOP1 | 2 |